6 studies found for:    EXT2
Show Display Options
Rank Status Study
1 Active, not recruiting
Has Results
Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil)(V501-015 AM5; EXT1; EXT2(AM1))
Conditions: Cervical Cancer;   Genital Warts
Interventions: Biological: Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine;   Biological: Matching Placebo
2 Completed
Has Results
A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (0518-019 EXT2)
Condition: HIV Infections
Interventions: Drug: raltegravir potassium;   Drug: Comparator: placebo
3 Completed
Has Results
A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (MK0518-018 EXT2)
Condition: HIV Infections
Interventions: Drug: raltegravir potassium;   Drug: Comparator: Placebo
4 Active, not recruiting
Has Results
A Study to Examine the Effects of an Experimental Drug on Postmenopausal Osteoporosis (MK-0822-004 AM2; EXT1(AM1); EXT2(AM2); EXT3)
Condition: Osteoporosis
Interventions: Drug: MK0822;   Dietary Supplement: Vitamin D3;   Dietary Supplement: Calcium Carbonate;   Drug: Placebo
5 Terminated Three Cycle Extension Study Evaluating Safety and Efficacy of a 25 mg Daily Dose of Proellex® In Pre-Menopausal Women With Leiomyomata Who Have Previously Completed ZPU 003 Ext
Condition: Uterine Fibroids
Intervention: Drug: Proellex®
6 Enrolling by invitation An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
Condition: Schizophrenia
Interventions: Drug: ALKS 9072, Low Dose;   Drug: ALKS 9072, High Dose

Indicates status has not been verified in more than two years